2020. Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s100. DOI:https://doi.org/10.25251/skin.4.supp.100.